Perceptive Advisors’s Orchestra BioMed OBIO Stock Holding History

Perceptive Advisors’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.7M	Hold	5,037,906	–	–	0.33%	58
2026 Q1	$21.4M	Sell	5,037,906 -89,350	-2%	-$380K	0.42%	51
2025 Q4	$21.3M	Sell	5,127,256 -165,300	-3%	-$667K	0.38%	60
2025 Q3	$13.1M	Buy	5,292,556 +700,000	+15%	+$1.93M	0.38%	50
2025 Q2	$12.3M	Hold	4,592,556	–	–	0.46%	49
2025 Q1	$19.7M	Hold	4,592,556	–	–	0.69%	36
2024 Q4	$18.4M	Hold	4,592,556	–	–	0.51%	43
2024 Q3	$23.6M	Buy	4,592,556 +2,046,675	+80%	+$13.4M	0.5%	51
2024 Q2	$20.7M	Hold	2,545,881	–	–	0.5%	55
2024 Q1	$13.4M	Buy	2,545,881 +113,792	+5%	+$771K	0.23%	70
2023 Q4	$22.2M	Hold	2,432,089	–	–	0.5%	49
2023 Q3	$21.2M	Buy	2,432,089 +379,221	+18%	+$2.55M	0.71%	41
2023 Q2	$14.4M	Sell	2,052,868 -225,358	-10%	-$3.42M	0.42%	59
2023 Q1	$44.6M	Buy	+2,278,226	New	+$26.4M	1.32%	20
2022 Q2	–	Sell	-450,000	Closed	-$4.46M	–	119
2022 Q1	$4.46M	Hold	450,000	–	–	0.09%	109
2021 Q4	$4.54M	Hold	450,000	–	–	0.07%	123
2021 Q3	$4.45M	Hold	450,000	–	–	0.06%	123
2021 Q2	$4.59M	Hold	450,000	–	–	0.06%	127
2021 Q1	$5.04M	Hold	450,000	–	–	0.06%	114
2020 Q4	$5.76M	Hold	450,000	–	–	0.06%	117
2020 Q3	$4.95M	Buy	+450,000	New	+$5.05M	0.07%	102

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Perceptive Advisors's OBIO Position: Q2 2026 in Review

Perceptive Advisors held its Orchestra BioMed (OBIO) position steady in Q2 2026 at 5,037,906 shares worth $21.7M. The position accounts for 0.33% of the portfolio, ranked #58.

Perceptive Advisors first reported a position in OBIO in Q3 2020 and has held it in 21 quarters since. The position peaked at $44.6M in Q1 2023. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

Perceptive Advisors held 5,037,906 shares of Orchestra BioMed worth $21.7M as of Q2 2026.
Perceptive Advisors left its Orchestra BioMed share count unchanged in Q2 2026.
Orchestra BioMed made up 0.33% of Perceptive Advisors's portfolio in Q2 2026, its #58 holding.
Perceptive Advisors first reported a position in Orchestra BioMed in Q3 2020 and has held it in 21 quarters since.
Perceptive Advisors's Orchestra BioMed position peaked at $44.6M in Q1 2023.
77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.